# Run record — anthropic/claude-opus-4-7 run 2 (v3 prompt)

## Metadata

- **Model:** anthropic/claude-opus-4-7
- **Interface:** Claude Code Agent tool sub-agent invocation (parallel with run 3); no system prompt, no tools, fresh context
- **Run number:** 2
- **Timestamp:** 2026-05-23
- **Reasoning mode:** Implicit (Opus 4.7 default)
- **Total tokens:** 26,620
- **Estimated cost:** $0.00 (sub-agent invocation, billed to parent)

## Prompt sent

v3 — standard Itô vol drag. See `prompt.md`.

## Model output (verbatim)

Here's a schedule designed to maximize NFV by spreading AMT exposure across years to stay near (but not far above) the AMT crossover, then disqualifying-disposition-free LTCG sale at year 4.

**Key inputs computed:**
- Spread at exercise = $198/share
- μ_geometric = 0.17 − 0.72²/2 = 0.17 − 0.2592 = **−0.0892/yr** (negative drift)
- Year-4 median price = $200 × e^(−0.0892 × 4) ≈ $200 × 0.6998 ≈ **$140/share**
- 2026 MFJ AMT exemption ≈ $137,000, phaseout begins ~$1.252M
- Regular tax on $300K MFJ ≈ $60K federal + ~$22K CA ≈ tentative regular tax baseline
- AMT crossover headroom (additional AMTI before AMT > regular) ≈ ~$240K-$280K/yr at this income → roughly **1,200–1,400 ISOs/yr** before triggering material AMT
- To exercise all 20,000 in 4 years, must accept significant AMT in at least some years
- CA AMT (7%) also bites; CA has no separate ISO LTCG break beyond federal qualifying treatment

**Strategy:** Front-load modestly (capture qualifying holding period clock early, since year-4 sale needs >2yr from grant AND >1yr from exercise — all four tranches qualify by EOY4). Exercise more in Y1–Y2 when shares are still expected at higher prices (negative drift means later exercises lock in smaller AMT spread, but you'd rather have the qualifying clock running). Balance: roughly equal tranches, slightly front-loaded.

| Year | Shares to exercise | Cash tax owed (then-year dollars) | Cumulative NFV (end-of-year-4 dollars) |
|------|--------------------|-----------------------------------|----------------------------------------|
| 1    | 5,500              | ~$285,000                         | —                                      |
| 2    | 5,500              | ~$250,000 (spread shrinks as FMV drifts down to ~$183) | — |
| 3    | 4,500              | ~$175,000 (FMV ~$167)             | —                                      |
| 4    | 4,500              | ~$140,000 (FMV ~$153; sold same year → DD, ordinary) | — |

**Year-4 sale:** All 20,000 sold at median $140. Shares exercised Y1–Y3 qualify for LTCG (held >1yr, >2yr from grant). Y4 tranche is a disqualifying disposition → ordinary income on lesser of spread-at-exercise or gain.

**NFV calculation sketch (end-of-Y4 dollars, 5.5% opportunity cost on taxes paid early):**
- Gross sale proceeds: 20,000 × $140 = $2,800,000
- Exercise cost: 20,000 × $2 = $40,000 (paid across years, grossed up at 5.5%)
- Federal LTCG (23.8% incl. NIIT) + CA (13.3%) on 15,500 qualifying shares: gain ≈ ($140 − $2) × 15,500 = $2,139,000 → tax ≈ ~$793K
- Y4 DD on 4,500 shares: ordinary tax on gain ≈ $621K × ~45% combined ≈ $279K (replaces the $140K AMT estimate above for that tranche)
- AMT paid Y1–Y3 generates **AMT credit carryforward** recoverable starting Y4 against the regular-tax delta → recovers a meaningful chunk (~$300–400K over time, but only partially by EOY4)
- Idle cash forgone return on taxes paid early: ~$710K cumulative tax in Y1–Y3, opportunity cost ≈ $90–110K by EOY4

**Final NFV at end of year 4: ≈ $1,560,000**

---

**Caveats and flags:**

1. **The negative drift is the dominant variable.** With σ=0.72, vol drag (−25.9%/yr) overwhelms the 17% arithmetic return — median outcome is the stock *falls* to ~$140. If you believe the arithmetic mean more than the median, the right move is to exercise *less* and hold cash; if you believe the median, exercising at all is questionable since you're paying tax on a $198 spread to capture a likely-declining asset.
2. **Concentration risk is severe.** $4M notional in one name at 72% vol means ~30% chance of a >50% drawdown in any given year. Strongly consider a protective put collar or staged sales as shares qualify, rather than holding all 20K to EOY4.
3. **AMT credit recovery is slow.** Front-loading AMT in Y1 means the credit may take 5–10+ years to fully recover against regular tax — the NFV number above only captures partial recovery by EOY4.
4. **Alternative worth modeling: exercise-and-sell-same-year (all DD).** Skips AMT entirely, all ordinary income, but you keep cash liquid and avoid concentration. At 72% vol with negative median drift, this likely *beats* the qualifying-disposition schedule on a risk-adjusted basis.
5. **Alternative: exercise only up to AMT crossover each year (~1,300 shares/yr = 5,200 total).** Leaves 14,800 unexercised at EOY4 but pays near-zero incremental tax. Lower NFV in the median case, but much better Sharpe.
6. **Numbers are approximations.** Real tax calc requires modeling AMT exemption phaseout interaction, CA AMT separately, NIIT thresholds, and the AMT credit ordering rules. A proper optimizer (e.g., one that jointly solves tax + hedging + concentration across scenarios) would likely produce a different schedule, especially given the volatility profile.
7. **Confirm grant date qualifying status.** January 2022 grant → 2-year-from-grant clock satisfied for any exercise from Jan 2024 onward, so all Y1–Y4 exercises clear the grant-side test; only the 1-year-from-exercise test gates Y4 tranche.

## Scoring

| Field | Value |
|---|---|
| Recommended Y1 / Y2 / Y3 / Y4 shares | 5,500 / 5,500 / 4,500 / 4,500 |
| Model's stated final NFV | $1,560,000 |
| **True NFV under recommended schedule** | **$372,032** |
| Delta vs deterministic optimum ($725,912) | -$353,880 |
| Stated-vs-true ratio | **4.19×** |
| Applied Itô vol drag correctly? | Yes (μ_geo = −0.0892, Y4 = $140 via continuous compounding) |
| Mentioned CA AMT? | Yes |
| Mentioned 2026 phaseout change? | Used phaseout starting $1,252,000 — close to the post-OBBBA 2026 figure ($1M MFJ); marginally stale |
| Identified disposition-period constraint? | Yes (flagged Y4 tranche as DD) |
| Notes | Identified own AMT-crossover number (~1,200-1,400 shares/yr) and recommended ~5K/yr anyway. Consistent with run 1 — high reasoning quality, stated dollar values exceed schedule's actual outcome by ~4×. |
